Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
45 /100
MEDIUM RISK
Score updated Aug 28, 2026

AVIR — Atea Pharmaceuticals, Inc. Dilution Risk Tracker

Track AVIR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track AVIR — Get alerts when the score changes →

As of August 28, 2026, Atea Pharmaceuticals, Inc. (AVIR) has a DilutionWatch DilutionScore of 45/100, rated MEDIUM dilution risk. Atea Pharmaceuticals, Inc. has a market capitalization of $373.73M, 80.20M shares outstanding, 129 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
39
💰 Cash Runway
65
📊 Float Risk
25
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 7%
💰 Capital Raise model 15%
• Under 12 months cash (6mo)
🔔 Track AVIR — Get forecast alerts →

Market Data

Market Cap$373.73M
Shares Outstanding80.20M
Float60.24M
Cash$76.55M
Debt$634.0K
Short InterestN/A

Institutional Holdings

QoQ: ↑ 17.3% shares (2026Q1 vs prior)
129 institutional holders · 67.30M shares
#1 FMR LLC 11.95M shares
#2 BlackRock, Inc. 8.44M shares
#3 BML Capital Management, LLC 7.06M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest7.53M
Days to Cover18.0
% of Float12.5%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2020-12-31
4 INSIDER TRANSACTION 2026-03-13
4 INSIDER TRANSACTION 2026-02-03
4 INSIDER TRANSACTION 2026-02-03
4 INSIDER TRANSACTION 2026-02-03
Full SEC filing analysis available with free account

Recent News

No recent news

Factual AVIR Dilution Snapshot

Atea Pharmaceuticals, Inc. (AVIR) has a DilutionScore of 45/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track AVIR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking AVIR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for AVIR
AVIR FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.